Ali Hassoun is an Infectious Disease physician affiliated with Mayo Clinic in Florida. OpenAlex indexes 107 publications with 1,255 citations (h-index 15); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
420 Lowell Dr SE
Suite 301
Huntsville, AL 358013754
Telephone
256-265-7955Registry record last updated 10 Oct 2012.
Clinical trials
- TEM-PCR™ Prospective Clinical Utility Study
Sponsor: Diatherix Laboratories, LLC
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
24 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year202514 payments$29,508openpaymentsdata.cms.gov ↗
- Melinta Therapeutics, LLCProgram year202514 payments
- Astellas Pharma US IncProgram year20258 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
83.1%Lipopeptide Antibacterial25.5%Daptomycin100%Part D≥80 patientsCephalosporin Antibacterial16.8%Cefepime Hcl85%Ceftriaxone9%Cefazolin Sodium6%Part D<11 patients+ 15 more classes in this area
Sensory organs
10.6%Aminoglycoside Antibacterial8.8%Tobramycin Sulfate90%Gentamicin Sulfate10%Part D<11 patientsFluoroquinolone Antibacterial1.8%Ciprofloxacin Hcl100%Part D≥16 patientsBlood & clotting
4%Salt solutions4%Sodium Chloride100%Part D≥13 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Dosing and Administration Strategies of Tocilizumab in Patients With COVID-19: A Retrospective Cohort Analysis
Annals of Pharmacotherapy
2023 - Myocarditis presentation following COVID-19 virus infection versus COVID-19 vaccination.
PubMed
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Edith Perez, MD
Mayo Clinic in Florida
Vivek Kumbhari, MD
Mayo Clinic in Florida
Joseph Blackshear, MD
Mayo Clinic in Florida
Jeffrey Hosenpud, MD
Mayo Clinic in Florida
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”